
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
RVX | Toronto | CAD | Real-time | |
RVXCF | OTC Markets | USD | Delayed | |
RVX | CBOE Canada | CAD | Real-time | |
RVX | Frankfurt | EUR | Delayed |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.
Name | Age | Since | Title |
---|---|---|---|
Donald J. McCaffrey | - | 2003 | Co-Founder, Chairman, President, CEO & Secretary |
Kelly Bret McNeill | - | 2006 | Lead Independent Director |
Kenneth J. Zuerblis | 65 | 2010 | Independent Director |
Siu Lun To | 55 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review